Oxford, UK – 30 April 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has extended its high-quality whole exome sequencing services with a targeted Familial Sequencing and Analysis Service. Ideal for investigators of inherited disease, the new service delivers multi-genome analysis of related samples for the detection of causative, de novo and disease susceptibility mutations. With a fully optimised workflow, OGT offers the entire targeted next generation sequencing pipeline, from project design through to end-point mutation discovery and extensive variant annotation. Uniquely, OGT’s service delivers all results in user friendly report that allows researchers to rapidly identify meaningful results without additional bioinformatics resource. To mark the expansion of its services, OGT has announced a special offer of 3 whole exome sequencing and analyses for the price of 2. The offer runs until the 14th of June 2013 and includes consultation with experienced biologists and bioinformaticians for project and capture design to provide the most uniform 50x coverage. The service promises an 8-week turnaround from DNA sample submission to a fully annotated and interactive data report for easy to interpret meaningful results. The report provides rapid comparative analysis for Mendelian violations, proband variants, recessive inheritance and compound heterozygotes.
To find out more, please visit the OGT website or download the Familial Sequencing and Analysis Product Profile.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.com
W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomic Solutions comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomics, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
